The Firm represented the underwriters, led by Barclays Bank PLC, Citigroup Global Markets Europe AG and Well Fargo Securities Europe S.A., in connection with the public offering by American Medical Systems Europe B.V. (“AMS Europe”) of €1.5 billion of debt securities, fully and unconditionally guaranteed by Boston Scientific Corporation (“Boston Scientific”), consisting of €850 million of 3.000% Senior Notes due 2031 and €650 million of 3.250% Senior Notes due 2034. Boston Scientific intends to use the net proceeds from the offering, together with cash on hand, to fund the repayment at maturity of AMS Europe's 0.750% senior notes due March 8, 2025, and to pay accrued and unpaid interest with respect to such notes, and for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.
The Simpson Thacher team included Roxane Reardon, Patrick Baron, J. Carr Gamble and Leandra Kede Yomo (Capital Markets); Jonathan Cantor and Edward Grais (Tax); Alysha Sekhon and Christian Bond (Intellectual Property); Michael Isby (Environmental); Jeanne Annarumma and Pasco Struhs (Executive Compensation and Employee Benefits); and Jennie Getsin (FINRA/Blue Sky).